A Phase 1 Study of Ly2801653 in Patients with Advanced Cancer

ID Number 13-1884

Principal Investigator(s)
Randall Holcombe

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called LY2801653. An experimental drug is one that is not approved by the United States Food and Drug Administration (FDA) for use except in research studies. 

This research study aims to:
 Test the safety of LY2801653 at different dose levels
 Find out how LY2801653 is distributed, broken down, and passed out of your body
 Find out what effects, good and/or bad, it has on you and your advanced cancer

Contact Information

Recruiting Patients: No